Personal Finance

Here's Why Acceleron Pharma Rose 24% in August

A businessman drawing a yellow step chart with a positive trend.

What happened

Shares of Acceleron Pharma (NASDAQ: XLRN) jumped exactly 24% last month, according to data provided by S&P Global Market Intelligence . That follows a 10.2% drop from July . What's going on?

The volatility actually isn't that surprising. Acceleron Pharma stock gained 42% on a single day at the end of June following encouraging data from a late-stage drug candidate. The data were promising enough for analysts to assume the drug candidate would receive marketing approval from the U.S. Food and Drug Administration. Despite that, Wall Street can't seem to make up its mind on the proper valuation for the pharma company. There's a good reason for that.

A businessman drawing a yellow step chart with a positive trend.

Image source: Getty Images.

So what

The late-stage drug candidate that reported results at the end of June was luspatercept, which is being developed with Celgene as a treatment for a group of rare blood disorders called myelodysplastic syndromes (MDS). The pharma giant thinks the drug could see peak sales of $2.2 billion. That would be pretty sweet for Acceleron Pharma considering it can receive up to $185 million in milestone payments, will split profit and loss in North America, and can earn royalties of at least 20% globally.

However, with a market cap of just $2.3 billion, some analysts have floated the idea that Celgene might just acquire Acceleron Pharma. Well, the 87% it doesn't already own. That idea might not be as crazy as it sounds, especially when considering the other promising mid-stage assets in the smaller company's pipeline.

Now what

In most cases, it's risky business for biopharma investors to assume that market approval is a slam dunk. Predicting that an acquisition is imminent is crazier still. However, there's a case to be made that Acceleron Pharma is undervalued at its current $2.3 billion market valuation. Investors with an above-average stomach for risk may want to poke around the company's financial statements and pipeline.

10 stocks we like better than Acceleron Pharma

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Acceleron Pharma wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of August 6, 2018

Maxx Chatsko has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Celgene. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

XLRN

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More